Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Bendamustine Monotherapy in Relapsed/Refractory T-cell Large Granular Lymphocytic Leukemia
ChiCTR2600121256Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in T-cell large granular lymphocytic leukemia, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate (ORR) at 2 months after treatment completion. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
bendamustine
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on ChiCTR2600121256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121256.